208 related articles for article (PubMed ID: 1998338)
21. Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I.
Overturf K; Al-Dhalimy M; Manning K; Ou CN; Finegold M; Grompe M
Hum Gene Ther; 1998 Feb; 9(3):295-304. PubMed ID: 9508047
[TBL] [Abstract][Full Text] [Related]
22. Compound mutations (R237X and L375P) in the fumarylacetoacetate hydrolase gene causing tyrosinemia type I in a Chinese patient.
Cao YY; Zhang YL; DU J; Qu YJ; Zhong XM; Bai JL; Song F
Chin Med J (Engl); 2012 Jun; 125(12):2132-6. PubMed ID: 22884142
[TBL] [Abstract][Full Text] [Related]
23. Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship.
Ploos van Amstel JK; Bergman AJ; van Beurden EA; Roijers JF; Peelen T; van den Berg IE; Poll-The BT; Kvittingen EA; Berger R
Hum Genet; 1996 Jan; 97(1):51-9. PubMed ID: 8557261
[TBL] [Abstract][Full Text] [Related]
24. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
[TBL] [Abstract][Full Text] [Related]
25. Hereditary tyrosinemia type I-associated mutations in fumarylacetoacetate hydrolase reduce the enzyme stability and increase its aggregation rate.
Macias I; Laín A; Bernardo-Seisdedos G; Gil D; Gonzalez E; Falcon-Perez JM; Millet O
J Biol Chem; 2019 Aug; 294(35):13051-13060. PubMed ID: 31300554
[TBL] [Abstract][Full Text] [Related]
26. Two novel FAH gene mutations in a patient with hereditary tyrosinemia type I.
Choi HJ; Bang HI; Ki CS; Lee SY; Kim JW; Song J; Shin MR; Lee YW; Lee DH; Park HD
Ann Clin Lab Sci; 2014; 44(3):317-23. PubMed ID: 25117105
[TBL] [Abstract][Full Text] [Related]
27. Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase.
Rootwelt H; Chou J; Gahl WA; Berger R; Coşkun T; Brodtkorb E; Kvittingen EA
Hum Genet; 1994 Jun; 93(6):615-9. PubMed ID: 8005583
[TBL] [Abstract][Full Text] [Related]
28. Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.
Yang S; Siepka SM; Cox KH; Kumar V; de Groot M; Chelliah Y; Chen J; Tu B; Takahashi JS
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22229-22236. PubMed ID: 31611405
[TBL] [Abstract][Full Text] [Related]
29. Heterozygosity for an exon 12 splicing mutation and a W234G missense mutation in an American child with chronic tyrosinemia type 1.
Hahn SH; Krasnewich D; Brantly M; Kvittingen EA; Gahl WA
Hum Mutat; 1995; 6(1):66-73. PubMed ID: 7550234
[TBL] [Abstract][Full Text] [Related]
30. Molecular Aspects of the FAH Mutations Involved in HT1 Disease.
Morrow G; Angileri F; Tanguay RM
Adv Exp Med Biol; 2017; 959():25-48. PubMed ID: 28755182
[TBL] [Abstract][Full Text] [Related]
31. cDNA cloning, sequence analysis, and chromosomal localization of the gene for human carnitine palmitoyltransferase.
Finocchiaro G; Taroni F; Rocchi M; Martin AL; Colombo I; Tarelli GT; DiDonato S
Proc Natl Acad Sci U S A; 1991 Jan; 88(2):661-5. PubMed ID: 1988962
[TBL] [Abstract][Full Text] [Related]
32. Hereditary tyrosinemia type I--an overview.
Kvittingen EA
Scand J Clin Lab Invest Suppl; 1986; 184():27-34. PubMed ID: 3296130
[TBL] [Abstract][Full Text] [Related]
33. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells.
Wu G; Liu N; Rittelmeyer I; Sharma AD; Sgodda M; Zaehres H; Bleidissel M; Greber B; Gentile L; Han DW; Rudolph C; Steinemann D; Schambach A; Ott M; Schöler HR; Cantz T
PLoS Biol; 2011 Jul; 9(7):e1001099. PubMed ID: 21765802
[TBL] [Abstract][Full Text] [Related]
34. A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation.
Dreumont N; Poudrier JA; Bergeron A; Levy HL; Baklouti F; Tanguay RM
BMC Genet; 2001; 2():9. PubMed ID: 11476670
[TBL] [Abstract][Full Text] [Related]
35. A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I.
Grompe M; St-Louis M; Demers SI; al-Dhalimy M; Leclerc B; Tanguay RM
N Engl J Med; 1994 Aug; 331(6):353-7. PubMed ID: 8028615
[TBL] [Abstract][Full Text] [Related]
36. The human fumarylacetoacetase gene: characterisation of restriction fragment length polymorphisms and identification of haplotypes in tyrosinemia type 1 and pseudodeficiency.
Rootwelt H; Kvittingen EA; Høie K; Agsteribbe E; Hartog M; van Faassen H; Berger R
Hum Genet; 1992 May; 89(2):229-33. PubMed ID: 1350265
[TBL] [Abstract][Full Text] [Related]
37. Messenger RNA as a source of transposase for sleeping beauty transposon-mediated correction of hereditary tyrosinemia type I.
Wilber A; Wangensteen KJ; Chen Y; Zhuo L; Frandsen JL; Bell JB; Chen ZJ; Ekker SC; McIvor RS; Wang X
Mol Ther; 2007 Jul; 15(7):1280-7. PubMed ID: 17440442
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine and its catabolites: from disease to cancer.
Tanguay RM; Jorquera R; Poudrier J; St-Louis M
Acta Biochim Pol; 1996; 43(1):209-16. PubMed ID: 8790725
[TBL] [Abstract][Full Text] [Related]
39. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.
Poudrier J; Lettre F; Scriver CR; Larochelle J; Tanguay RM
Mol Genet Metab; 1998 Jun; 64(2):119-25. PubMed ID: 9705236
[TBL] [Abstract][Full Text] [Related]
40. Enzyme defect in a case of tyrosinemia type I, acute form.
Furukawa N; Kinugasa A; Seo T; Ishii T; Ota T; Machida Y; Inoue F; Imashuku S; Kusunoki T; Takamatsu T
Pediatr Res; 1984 May; 18(5):463-6. PubMed ID: 6145143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
